Glutamine availability regulates cDC subsets in tissue

Area of Science:

• Immunology
• Cancer Metabolism
• Cell Biology

Background:

• Tumor cells consume glutamine for growth, creating a nutrient-poor microenvironment.
• The impact of this glutamine deficiency on immune cells, particularly dendritic cells, is not well understood.
• Conventional dendritic cells (cDCs) are crucial for initiating anti-tumor immune responses.

Purpose of the Study:

• To investigate how tumor-induced glutamine deficiency affects conventional dendritic cells (cDCs) in the tumor microenvironment.
• To determine the specific impact on cDC subsets, especially the immunologically important cDC1 subset.
• To elucidate the mechanisms by which tumors exploit glutamine metabolism to evade immune surveillance.

Main Methods:

• Utilized mouse models of soft tissue sarcomas.
• Employed glutamine antagonists and genetic/pharmacological inhibition of glutamine utilization.
• Analyzed the frequency, proliferation, and survival of dendritic cell subsets (cDC1 and cDC2).
• Investigated the role of the mTOR signaling pathway.

Main Results:

• Tumor-associated glutamine deficiency significantly reduces the number and frequency of conventional dendritic cells (cDCs).
• Type 1 conventional dendritic cells (cDC1s) are particularly sensitive to glutamine deprivation, showing decreased proliferation and survival.
• Glutamine antagonism did not affect dendritic cell precursor numbers, indicating a specific impact on cDC maturation and maintenance.
• The nutrient-sensing mTOR pathway appears to be involved in mediating glutamine's effect on cDC1s.

Conclusions:

• Tumors co-opt glutamine metabolism to deplete the tumor microenvironment, thereby impairing the function and survival of critical anti-tumor immune cells like cDC1s.
• This glutamine dependence of cDC1s represents a novel mechanism of tumor immune evasion.
• Targeting glutamine metabolism holds promise for enhancing anti-tumor immunity and cancer immunotherapy.